Lipella Pharmaceuticals Inc. - Common Stock (LIPO)
2.7100
+0.0400 (1.50%)
Lipella Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for urological conditions, particularly those affecting the bladder
The company is engaged in advancing its proprietary drug candidates through clinical trials, aiming to address unmet medical needs in the treatment of bladder diseases such as interstitial cystitis and overactive bladder. By leveraging advanced drug delivery technologies and focusing on targeted treatment approaches, Lipella seeks to improve patient outcomes and enhance the quality of life for individuals suffering from these debilitating conditions.
New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions.
Lipella Pharmaceuticals shares are trading higher Monday after the company announced the enrollment of the first patients in its Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP).
Shares of SOPHiA GENETICS SA (NASDAQSOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
